Page last updated: 2024-11-07

hydrogen sulfite

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Hydrogen sulfite, also known as bisulfite, is an ion with the formula HSO3-. It is the conjugate base of sulfurous acid (H2SO3) and is formed by the reaction of sulfur dioxide (SO2) with water. Hydrogen sulfite is a colorless, odorless gas that is soluble in water. It is a common industrial chemical used in a variety of applications, including as a reducing agent, a bleaching agent, and a preservative. Hydrogen sulfite is also used in the production of paper, textiles, and food products. In food chemistry, hydrogen sulfite is used as an antioxidant, a color stabilizer, and a preservative. It is found in many processed foods, including wines, beer, and dried fruits. Hydrogen sulfite is also used in the treatment of wastewater and in the production of pharmaceuticals. The importance of hydrogen sulfite lies in its versatility and effectiveness in various chemical processes. Its reducing properties make it useful for bleaching, while its preservative qualities allow it to extend the shelf life of food products. The study of hydrogen sulfite is driven by the need to understand its environmental impact, its health effects, and its potential applications in various industries. Its presence in food and industrial processes necessitates research into its safety and potential risks. The study of hydrogen sulfite also involves exploring its chemistry, its reactions with other substances, and its applications in various fields.'

Cross-References

ID SourceID
PubMed CID104748
CHEMBL ID1794637
CHEBI ID29214
CHEBI ID17137
MeSH IDM0125104

Synonyms (41)

Synonym
HSO3
sulphonic acid
[sho2(oh)]
hydrogentrioxosulfate(1-)
hydrogen(trioxidosulfate)(1-)
hydrogentrioxosulfate(iv)
hydridohydroxidodioxidosulfur
CHEBI:29214 ,
bisulphite
hydrosulfite anion
hsho3
hso3(-)
monohydrogentrioxosulfate
hydrogensulfite(1-)
hydrogen sulfite(1-)
[so2(oh)](-)
sulfonic acid
hydroxidodioxidosulfate(1-)
acide sulfonique
sulfonsaeure
CHEBI:17137
hso3-
hydrogen sulfite
bisulfite
15181-46-1
sulfite (hso3 1-)
sulfite (hso3)-
sulfite, hydrogen
sulfite lye
hydrogensulfite
bdbm26991
unii-oj9787wblu
oj9787wblu ,
bisulfite ion
sulfurous acid, ion(1-)
LSNNMFCWUKXFEE-UHFFFAOYSA-M
DTXSID5075311
CHEMBL1794637
Q27110050
Q27109972
Q27102231

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Because little information is available concerning the extent of intermolecular protein cross-linking during acrolein toxicity in cells, we used an antibody against a known target for toxic carbonyls, the chaperone protein Hsp90, to detect the formation of high-mass protein complexes in acrolein-exposed A549 cells."( Intermolecular protein cross-linking during acrolein toxicity: efficacy of carbonyl scavengers as inhibitors of heat shock protein-90 cross-linking in A549 cells.
Burcham, PC; Raso, A; Tan, D; Thompson, C, 2007
)
0.34
" We did not observe any adverse events or significant endothelial cell loss (p = 0."( Efficacy and safety of low-concentration, bisulphite-containing, intracameral epinephrine and topical atropine treatments for the prevention of intraoperative floppy iris syndrome.
Bulut, AE; Esen, F; Toker, E, 2018
)
0.48

Pharmacokinetics

ExcerptReferenceRelevance
" It is also rapidly degraded in collected pharmacokinetic plasma and blood samples even stored under - 70 °C."( A stability indicating LC-MS/MS method for quantification of a NOX Inhibitor R14 in its bisulfite adduct form for pharmacokinetic studies.
Liang, D; Lin, SY; Ma, J; Wang, Y; Xie, H, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" On the other hand, bioavailability of oral mucosal, rectal and oral administration was about 100, 63."( A novel administration route of edaravone--II: mucosal absorption of edaravone from edaravone/hydroxypropyl-beta-cyclodextrin complex solution including L-cysteine and sodium hydrogen sulfite.
Ishii, F; Mizuno, K; Sato, T, 2010
)
0.55
" In the present study, we performed a global analysis of DNA methylation patterns in human keratinocytes exposed to 900 MHz RF-EMFs for 1 h at a low dose rate (estimated mean specific absorption rate (SAR) < 10 mW/kg)."( Analysis of global DNA methylation changes in human keratinocytes immediately following exposure to a 900 MHz radiofrequency field.
Butterworth, JW; Cantu, JC; Echchgadda, I; Payne, JA; Peralta, XG, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" To study the effects of prior acrolein dosing on the severity of influenza A viral infection, male BALB/c mice received acrolein (1mg/kg) or saline (control) via oropharyngeal aspiration either 4- or 7-days prior to intranasal inoculation with either influenza A/PR/8/34 virus or vehicle."( Prior exposure to acrolein accelerates pulmonary inflammation in influenza A-infected mice.
Burcham, PC; Henry, PJ; Ong, FH, 2012
)
0.38
" Reducing enzyme dosage at 16% solids loading from 46 to 11."( Effect of high dry solids loading on enzymatic hydrolysis of acid bisulfite pretreated Eastern redcedar.
Atiyeh, HK; Dunford, NT; Hiziroglu, S; Ramachandriya, KD; Wilkins, M, 2013
)
0.39
" All patients received the first cycle of TMZ at a dosage of 150 mg/m(2) starting on the second or third postsurgical day."( Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Albanese, V; Barbagallo, GM; Caltabiano, R; Certo, F; Lanzafame, S; Longo, A; Motta, F; Palmucci, S; Paratore, S; Parra, HS; Privitera, G; Scaglione, G, 2014
)
0.4
" In addition, FLT1 hypermethylation and gene suppression appeared in primary human lymphocytes in a dose-response manner following COEs treatment."( FLT1 hypermethylation is involved in polycyclic aromatic hydrocarbons-induced cell transformation.
Chen, L; Chen, S; Chen, W; Dong, G; Duan, H; He, Z; Li, D; Li, H; Li, Q; Niu, Y; Wang, Q; Wang, Z; Xiao, Y; Xing, X; Ye, L; Yu, D; Zhang, R; Zheng, Y, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
sulfur oxoanion
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Metabolism14961108
Amino acid and derivative metabolism250260
Sulfur amino acid metabolism2763
Degradation of cysteine and homocysteine1538
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
nitrate reduction V (assimilatory)426
alkylnitronates degradation350

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)Ki27,641.94000.00001.372610.0000AID1798763; AID1803484
Carbonic anhydrase 2Homo sapiens (human)Ki41,841.94000.00000.72369.9200AID1798763; AID1803485
Carbonic anhydrase 4Homo sapiens (human)Ki30,052.42500.00021.97209.9200AID1798763
Carbonic anhydraseMethanosarcina thermophilaKi200,000.00000.06000.97148.5000AID1803493
Carbonic anhydrase 15Mus musculus (house mouse)Ki30,052.42500.00091.884610.0000AID1798763
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1803254CA Inhibition Assay from Article 10.3109/14756366.2011.649268: \\Inhibition of the alpha- and beta-carbonic anhydrases from the gastric pathogen Helycobacter pylori with anions.\\2013Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 28, Issue:2
Inhibition of the alpha- and beta-carbonic anhydrases from the gastric pathogen Helycobacter pylori with anions.
AID1798763CA Inhibition Assay from Article 10.1016/j.bmcl.2008.12.082: \\Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions.\\2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions.
AID1803487ChEMBL_158307 (CHEMBL763192) from Article 10.1016/j.bmc.2016.05.029: \\Anion inhibition profiles of a-, u00DF- and u00BF-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.\\2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID1803484ChEMBL_158304 (CHEMBL763189) from Article 10.1016/j.bmc.2016.05.029: \\Anion inhibition profiles of a-, u00DF- and u00BF-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.\\2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID1803486ChEMBL_158306 (CHEMBL763191) from Article 10.1016/j.bmc.2016.05.029: \\Anion inhibition profiles of a-, u00DF- and u00BF-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.\\2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID1803485ChEMBL_158305 (CHEMBL763190) from Article 10.1016/j.bmc.2016.05.029: \\Anion inhibition profiles of a-, u00DF- and u00BF-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.\\2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID1803491ChEMBL_158311 (CHEMBL763368) from Article 10.1016/j.bmc.2016.05.029: \\Anion inhibition profiles of a-, u00DF- and u00BF-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.\\2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID1803493ChEMBL_158313 (CHEMBL763370) from Article 10.1016/j.bmc.2016.05.029: \\Anion inhibition profiles of a-, u00DF- and u00BF-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.\\2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,140)

TimeframeStudies, This Drug (%)All Drugs %
pre-199051 (4.47)18.7374
1990's42 (3.68)18.2507
2000's197 (17.28)29.6817
2010's612 (53.68)24.3611
2020's238 (20.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.06 (24.57)
Research Supply Index7.06 (2.92)
Research Growth Index5.26 (4.65)
Search Engine Demand Index98.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.26%)5.53%
Reviews41 (3.55%)6.00%
Case Studies1 (0.09%)4.05%
Observational1 (0.09%)0.25%
Other1,110 (96.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]